Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The reports are tied to United States. The first report grouped here was at 30 Sept 2026, 23:42 UTC. The headline in use is “Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript”. This note is SignalsMonitor's own briefing, not the publisher's article.